This phase III trial is trying to understand how well two targeted cancer drugs (enfortumab vedotin and pembrolizumab) work together to treat patients with urothelial cancer, compared to standard of care chemotherapy.
This trial is treating patients with urothelial cancer (a type of bladder cancer).
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
Astellas Pharma Inc.
Eligible patients will be randomised to Arm A, Arm B or Arm C of the trial. At this stage, only Arm A and Arm B are accepting patients. Patients will either receive intravenous Enfortumab vedotin and pembrolizumab (in Arm A of the trial) or standard of care chemotherapy (containing Gemcitabine and Cisplatin or Carboplatin, in Arm B of the trial) over a three-week cycle.
Recruiting Hospitals Read More